19815 Bay Branch Rd
Andalusia, Alabama 36420
(334) 222-2523
HELPLINE: 1-877-530-0002



Facebook    

 

SCAMHC is an approved Mental Health site for the National Health Service Corps Loan Repayment program.  Find out the program details and see if you qualify by visiting: http://nhsc.hrsa.gov/

SCAMHC is an Equal Opportunity Provider and Employer and maintains a Drug-Free Workplace

 

 

 

 


powered by centersite dot net
Medications
Resources
Basic InformationLatest News
COVID Drug Remdesivir Could Cost Up to $3,120 Per Patient, Maker SaysHigh Costs Lead Millions of Americans to Shop Abroad for Rx DrugsFDA Pulls Emergency Approval of Hydroxychloroquine for COVID-19How Ritalin Works in the BrainFDA Pulls Heartburn Drug Zantac From MarketTaking More Antibiotics May Up Odds for HospitalizationAllergy Med Singulair to Get 'Black Box' Warning Over Psych Side Effects: FDAU.S. Drug Prices Have Risen Three Times Faster Than InflationUse Pot? It Can Interact With Your Meds in Harmful WaysToo Many Antibiotics, Opioids Given to Dental Patients in the ERBrand-Name Rx Rise After Docs Get Drug Company Perks: StudyAs Prices Rise for Parkinson's, Alzheimer's Meds, Patients Go WithoutPrice Hikes Have Patients Turning to Craigslist for Insulin, Asthma InhalersAI May Help Guide Patients to Most Effective Antidepressant1 in 4 Gets Unneeded Antibiotics at Children's HospitalsStudy Finds 'No Clear Rationale' for 45% of Antibiotic PrescriptionsAre Antibiotics a Recipe for Obesity in Childhood?Do You Take Warfarin? Time of Day Might Not MatterNew Drugs Getting FDA's Blessing Faster, but Is That a Good Thing?Health Tip: Acetaminophen SafetyTwo More Heartburn Meds Recalled Due to Possible CarcinogenMany Drugstores Misinform on Disposal of Unused MedsHealth Tip: How to Remember to Take Your MedicationsFDA to Allow States to Import Prescription Drugs From Other CountriesOver 40% of Antibiotics Could Be 'Inappropriately' PrescribedFDA Testing Levels of Carcinogen in Diabetes Drug MetforminTaking Several Prescription Drugs May Trigger Serious Side EffectsPenicillin Allergy Less Common Than Thought: StudyMany Older Americans Misuse Antibiotics: PollAntibiotics Not Recommended for Most Toothaches, New Guideline SaysHealth Tip: Taking Anti-Inflammatory DrugsMany Common Meds Could Alter Your MicrobiomeWhen Meds Are Free, Patients Take Them More OftenMaker Halts Distribution of Generic Zantac Due to Possible CarcinogenKids Often Prescribed Drugs 'Off-Label,' Raising ConcernsHeartburn Drug Zantac May Contain Small Amounts of Known Carcinogen, FDA SaysHealth Tip: Take Over-the-Counter Medication WiselyA Prescription for Medicating Your Child SafelyHealth Tip: Taking Dietary SupplementsTrump Administration Announces Plan to Allow Cheaper Drug Imports From CanadaAre Too Many Kids Prescribed Antihistamines?Some Meds and Driving a Dangerous DuoHealth Tip: Giving Medicine Safely to ChildrenHigher Cost of New Cholesterol Drugs Putting Patients at Risk: StudyMany Americans Take Antibiotics Without a PrescriptionHealth Tip: Packing Prescriptions for Travel
Questions and AnswersVideosLinksBook Reviews
Related Topics

Anxiety Disorders
Depression: Depression & Related Conditions
Mental Disorders
Mental Health Professions

Maker Halts Distribution of Generic Zantac Due to Possible Carcinogen

HealthDay News
by -- Robert Preidt
Updated: Sep 19th 2019

new article illustration

THURSDAY, Sept. 19, 2019 (HealthDay News) -- Novartis, the maker of a generic form of the popular heartburn drug Zantac, said Wednesday it will cease distribution of the medicine after investigations suggested that generic and branded versions contain a known carcinogen.

A distribution halt is not the same as a full recall, and it means that generic Zantac (ranitidine) remaining on store shelves can still be sold, CBS News reported.

The move stems from an announcement made last Friday by the U.S. Food and Drug Administration. In a statement, the agency said that a substance that could cause cancer had been found in some ranitidine heartburn and ulcer medicines, including the brand name drug Zantac, and the source of this contamination is being investigated.

Sanofi, the maker of Zantac, said in a statement on Wednesday that "there are currently no plans to stop distributing or manufacturing Zantac or other ranitidine products outside of Canada," and added that "we are conducting our own robust investigations to ensure we continue to meet the highest quality safety and quality standards."

While preliminary tests found low levels of the nitrosamine impurity N-nitrosodimethylamine (NDMA) in some ranitidine products, the FDA said last week that this does not mean patients taking the drugs should now stop using them.

NDMA is the same contaminant found in many brands of blood pressure and heart failure medications during the past year, leading to recalls.

Patients who are taking prescription ranitidine who want to stop using it should discuss alternatives with their health care provider, the FDA advised. Those taking over-the-counter (OTC) ranitidine could switch to other OTC heartburn medicines.

Several drugs are approved for the same or similar uses, the FDA noted.

NDMA is an environmental contaminant found in water and foods, including meats, dairy products and vegetables. It is classified as a probable human carcinogen.

"Drug impurities remain a major national concern," said Dr. David Robbins, associate chief of endoscopy at Lenox Hill Hospital in New York City. "While Zantac may prove safe in the long run, this latest statement adds confusion and concern, so my interim advice to patients is simple: switch to another drug … and of course, confirm with your doctor the need for an antacid."

The FDA said it's evaluating whether the low levels of NDMA in ranitidine pose a risk to patients and that it will post that information when it's available.

In a statement, Sanofi said that it "takes patient safety seriously, and we are committed to working with the FDA. Zantac OTC [over the counter] has been around for over a decade and meets all the specified safety requirements for use in the OTC market."

In the meantime, Dr. Janet Woodcock, director of the FDA's Center for Drug Evaluation and Research, said the FDA is working with international regulators and industry partners to find out where the contamination originated.

"The agency is examining levels of NDMA in ranitidine and evaluating any possible risk to patients," she said in a news release. "The FDA will take appropriate measures based on the results of the ongoing investigation."

Large amounts of NDMA may pose a risk, but the levels of NDMA found in ranitidine in preliminary tests barely exceed amounts found in common foods, according to the FDA.

Ranitidine decreases the amount of acid created by the stomach. OTC ranitidine is approved to prevent and relieve heartburn, and prescription ranitidine is approved for a number of uses, including treatment and prevention of ulcers of the stomach and intestines, and treatment of gastroesophageal reflux disease (GERD).

Similar contamination in heart medicines is also under investigation.

"The FDA has been investigating NDMA and other nitrosamine impurities in blood pressure and heart failure medicines called Angiotensin II Receptor Blockers [ARBs] since last year," Woodcock said. "In the case of ARBs, the FDA has recommended numerous recalls as it discovered unacceptable levels of nitrosamines."

More information

The U.S. Agency for Toxic Substances & Disease Registry has more on NDMA.